Relevance to redesigning aspirin therapeutic regimens.
The quantitative relationship between the plasma aspirin (ASA) concentrations and the various responses have not been established in man. Nevertheless, available information would suggest that the pharmacodynamic Emax model adequately describes both the inhibition of TxB2 production by ASA and the competitive role of salicylic acid (SA) in the reaction. Available pharmacokinetic data can be used to predict plasma ASA and SA levels following different ASA dosing regimen. Such information can be useful in designing prospective studies and managing patients who receive ASA.